AH-7921 Immunoassay Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting AH-7921 and its metabolites, such as laboratory-based mass-spectrometry, are expensive and require highly trained operators, posing a clinical and forensic challenge due to their high addictive potential and involvement in deaths.
Innovation Solution
Development of an immunoassay using novel and highly sensitive antibodies specific to AH-7921 and its metabolites, along with novel immunogens and substrates, allowing for selective detection and determination in samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If laboratory-based mass-spectrometry is used for detection, then measurement precision is improved, but device complexity and ease of operation deteriorate
Solution Approach 1:
The patent replaces complex mass-spectrometry equipment with a simpler immunoassay system using antibodies and detecting agents. The mechanical/physical system of mass spectrometry is substituted with a biochemical system that achieves comparable detection precision through antigen-antibody binding reactions, thereby reducing device complexity while maintaining measurement accuracy.
Solution Approach 2:
The patent introduces antibodies as intermediary detecting agents that specifically bind to AH-7921 and its metabolites. These antibody intermediaries enable detection without requiring complex mass-spectrometry equipment, simplifying the overall detection system while maintaining high measurement precision through specific immunological recognition.
2Measurement precision
If laboratory-based mass-spectrometry is used for detection, then measurement precision is improved, but ease of operation deteriorates
Solution Approach 1:
The patent replaces operator-intensive mass-spectrometry operations with a simpler immunoassay procedure. The complex operational steps of mass spectrometry are substituted with straightforward immunological reactions that can be performed with minimal training, thereby improving ease of operation while maintaining detection precision through the specificity of antibody-antigen binding.
Solution Approach 2:
The immunoassay system performs detection automatically through the inherent specificity of antibody-antigen binding reactions. The detecting agents self-recognize and bind to target analytes without requiring highly trained operators to interpret complex spectral data, thereby improving ease of operation while maintaining high measurement precision through the biological recognition system.
3Ease of operation
If immunoassay with novel antibodies is used, then ease of operation is improved, but manufacturing precision deteriorates
Solution Approach 1:
The patent applies local quality by designing antibodies with highly specific binding sites that recognize unique structural features of AH-7921 and its metabolites. The detecting agents are engineered with specific epitope recognition capabilities that ensure high manufacturing precision in terms of antibody specificity, while the overall assay remains easy to operate through standardized immunological procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoassay provides a cost-effective and operator-friendly method for detecting AH-7921 and its metabolites with high sensitivity and specificity, enabling efficient clinical and forensic analysis.
Implementation Method 1
an immunoassay for the selective detection and determination of 3,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and 3,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide. The immunoassay is underpinned by novel and highly sensitive antibodies.
Data Source
AI summary
Antibodies, immunoassay methods and kits for the detection and determination of 3,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and 3,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide, as well as the precursory immunogens, are described.